Docket No: AM100305 Patent

IÉ UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

Anita W-Y, Chan

10/016 229

Group Art No .:

1624

Application No.: Filed

Examiner:

November 2 2001

B. Coleman

For:

PROCESS FOR THE PREPARATION OF 1, 2, 3, 4, 8, 9, 10, 10a-

OCTAHYDRO-7bH-CYCLOPENTA[b][1, 4]DIAZEPINO- [6, 7, 1-hi]

Confirmation No.: Customer Number: 9006

25291

INDOLÉ DERIVATIVES

RECEIVED

Commissioner for Patents

PO Box 1450 Alexandria, VA 22313-1450 DEC 0 3 2003

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Preliminary Statements 1.

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made: (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU947815626US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

November 25. Date

Paula L. Dickey

2.						
		Inform	nation Disclosure Statement			
	а.	Щ	is filed within three months of the filing			
	b.	\boxtimes	is filed before the mailing date of a first			
	C.		is filed before the mailing date of a first request for continued examination und	er 37 CFR 1.114	ŀ.	· ·
	d.		is filed after the period specified in 2(a) mailing date of a final action under 37 a certification under 37 CFR 1.97(e) or	CFR 1.311. This	stateme	nt includes
	e.		is filed after the mailing date of a final a before payment of the issue fee. This under 37 CFR 1.97(e), <u>and</u> (ii) the fee	action or Notice of statement include	of Allowar les (i) a ce	nce but ertification
3.			fication under 37 CFR 1.97(e) and 1.70- undersigned attorney certifies	4(d)		
	a.		that each item of information contained Statement was first cited in any commin in a counterpart foreign application not filing of the statement, or	unication from a	foreign pa	atent office
	b.		that no item of information contained in Statement was cited in a communicatic counterpart foreign application or, to the the certification after making reasonab individual designated in 37 CFR 1.56(c the filing of the statement.	on from a foreigr e knowledge of le inquiry, was k	n patent of the person	ffice in a n signing ny
	c.		The undersigned attorney certifies that in the Information Disclosure Statemer a foreign application patent office in a was not received by any individual des	nt was cited in a counterpart forei ignated in 37 CF	communio gn applica	cation from ation and
	45.0		than thirty (30) days prior to the filing o	the statement.		
		A leg attac filed	y Cited Information ible copy of the patents, publications or hed form PTO 1449 is enclosed, except or entered the national stage after June S. patent application publication is enclo	that if this pater 30, 2003, no co	nt applicat	ion was
		No co form to the unde	ously Cited Information opy of the patents, publications or other PTO-1449 is enclosed because it has be o Office in a prior application which is re r 35 USC 120.	een previously o lied upon for an	cited by or earlier filir	submitted ng date
		Prior	application is Application Number	, filed on	of	for

Docket No: AM100305 Patent

□ Concise Explanation □ Documents cited above which are not in the English Language □ have been explained in the specification. □ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.	
Form PTO-1449 is enclosed in duplicate.	
Fee's Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00	
Method of Payment of Fees: Charge Deposit Account No. 01-1425 in the amount of \$180.00 A duplicate of this statement is enclosed.	
Instructions as to Overpayment/Underpayment: Credit any overpayment.and charge any underpayment to Deposit Account No. 01-1425.	
V L AVIA	
Kumbuly R. Huld Kimberly R. Hild	-
Attorney for Applicants	
Reg. No. 39,224	

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. 484 865 8610

			0. 5.	Con	nplete if Known	
Substitute for fo	rm 1449/PTO		S)	Application Number	10/016,229	
	INFORMATION DISC	LOSORE	10V 2 5 2003 %	Filing Date	November 2, 2001	
	STATEMENT BY AP	PLICANT.	24	First Named Inventor	Anita W-Y. Chan	
(use	as many sheets	as ne	sary)	Group Art Unit	1624	
			TRADEMARY	Examiner Name	B. Coleman	
Sheet	. 1	of.	1	Attorney Docket Number	AM100305	

	1.	-	, , , , , , , ,	_			Figures Appear		
			F	OREIGN P	ATENT DOCUMENTS				
Examiner	Cite	Foreign Patent Document			Name of Contrasts of	Date of Publication of	Pages, Columns, Lines,	1	
Initials*	No		(If Known)	Name of Patentee or Applicant of Cited document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т		

Kind Code (If Known)

	OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the stricle (when appropriate), title of the ferm (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/for country where outliers when the publisher of	т			
	3.	H.P. HARTER et al., Chimia, 30, 50-52, (1976)				

RECEIVED

Pages, Columns, Lines Where Relevant Passages or Relevant

DEC 0 3 2003 TECH CENTER 1600/2900

Examiner Signature	Date Considered
	Considered